Role of Dashang Guggulu and Shatpuspha Churna in PCOD in Corporate Sector Women

Phase 2

Not yet recruiting

• Conditions: Female pelvic inflammatory disorders in diseases classified elsewhere, (2) ICD-10 Condition: N948||Other specified conditions associated with female genital organs and menstrual cycle. Ayurveda Condition: Metabolic Disorders, (3) ICD-10 Condition: N948||Other specified conditions associated with female genital organs and menstrual cycle. Ayurveda Condition: MEDAHSTHITAKAPAKOPAH,

• Registration Number: CTRI/2023/08/055990
• Lead Sponsor: National Institute of Ayurveda(Deemed to be Novo),Jaipur

Brief Summary

In ayurveda conditions can correlate with PCOD like *Yonivyapada* (genital disorders), *Ashtoartavadushti3* (menstrual disorders) and *Nashtartava4* (secondary amenorrhea). The features of PCOD may also be correlated with *Pushpaghni Jataharini*5 having the clinical features like *Sthoulya* (obesity), *Lomashaganda* (hirsutism) or hairy and corpulent cheeks and *Vrithapushpa* (unfruitful ovulation/anovulation) with menstrualirregularities. Consideringthe pathology i.e formation and accumulation of cyst in periphery of ovary, PCODbear similar symptom as *Granthi* also *Sthoulya Samprapti6* & *Prameha Samprapti*7 alsopossesses some clinical features similar to PCOD. According to *Bhavprakasha8,* in female *rajah srava*occurs monthly, which causes purity        of *sharirika dosha*. Thismonthly purification of *doshas* prevent *prameha* in females. As whole metabolic process is disturbed in PCODwhich is considered as *dhatwagni vikara .*

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-07-31
• Study Start: 2023-10-08

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Female patients of age group between 21 to 40 years (Both married and unmarried) Patient having two out of three criteria- ASRM/ESHRE (Rotterdam) Criteria,2018 Oligo and /or anovulation Hyperandrogenism (clinical and /or biochemical).
• Polycystic ovaries (Confirmed on USG) BMI ≥23.

Exclusion Criteria

• ï¶Patient having any other disease causing oligomenorrhoea and anovulation excluding PCOD on above criteria.
• ï¶Any organic lesions of reproductive tract like T.B., carcinoma and congenital deformities or any other pelvic pathology.
• ï¶Patient suffering from hyperprolactinemia, adrenal hyperplasia, severe insulin resistance, androgen secreting neoplasm, thyroid abnormalities, Cushing’s syndrome, cardiac diseases will exclude.
• ï¶Current or previous (within last 3 months) use of OC pills, Glucocorticoids, anti-androgens, ovulation induction agents, anti-diabetic, anti-obesity drugs, or other hormonal drugs.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Physical Measurement & biochemical investigations for Medodusthi	90 Days
Changes in serum LH & FSH value	90 Days
Change in USG Report & other laboratory investigations for Aartavdusthi.	90 Days

Secondary Outcome Measures

Name	Time	Method
Changes in the Subjective Parameters of Medodusthi	and Aartavdusthi

Trial Locations

Locations (2)

Genpact Company; 🇮🇳 Jaipur, RAJASTHAN, India

National Institute of Ayurveda; 🇮🇳 Jaipur, RAJASTHAN, India

Genpact Company

🇮🇳Jaipur, RAJASTHAN, India

Rashmi Temani

Principal investigator

01414092008

rashmitemani@gmail.com